Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease.
- Author:
Sol KIM
1
;
Jun CHANG
Author Information
- Publication Type:Original Article
- Keywords: Respiratory syncytial virus; Glycoprotein; Recombinant baculovirus; Protective immunity
- MeSH: Administration, Intranasal; Animals; Baculoviridae; Eosinophilia; Glycoproteins; Immunity, Humoral; Immunization; Immunoglobulin A; Immunoglobulin G; Lung; Mice; Respiratory Syncytial Viruses; Respiratory Tract Diseases; T-Lymphocytes; Vaccination; Weight Loss
- From:Immune Network 2012;12(1):8-17
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract diseases in infancy and early childhood. Despite its importance as a pathogen, there is no licensed vaccine against RSV yet. The attachment glycoprotein (G) of RSV is a potentially important target for protective antiviral immune responses. Recombinant baculovirus has been recently emerged as a new vaccine vector, since it has intrinsic immunostimulatory properties and good bio-safety profile. METHODS: We have constructed a recombinant baculovirus-based RSV vaccine, Bac-RSV/G, displaying G glycoprotein, and evaluated immunogenicity and protective efficacy by intranasal immunization of BALB/c mice with Bac-RSV/G. RESULTS: Bac-RSV/G efficiently provides protective immunity against RSV challenge. Strong serum IgG and mucosal IgA responses were induced by intranasal immunization with Bac-RSV/G. In addition to humoral immunity, G-specific Th17- as well as Th1-type T-cell responses were detected in the lungs of Bac-RSV/G-immune mice upon RSV challenge. Neither lung eosinophilia nor vaccine-induced weight loss was observed upon Bac-RSV/G immunization and subsequent RSV infection. CONCLUSION: Our data demonstrate that intranasal administration of baculovirus-based Bac-RSV/G vaccine is efficient for the induction of protection against RSV and represents a promising prophylactic vaccination regimen.
